Nothing Special   »   [go: up one dir, main page]

RU2018144315A - КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ Download PDF

Info

Publication number
RU2018144315A
RU2018144315A RU2018144315A RU2018144315A RU2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A RU 2018144315 A RU2018144315 A RU 2018144315A
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
cdr
cmet
Prior art date
Application number
RU2018144315A
Other languages
English (en)
Other versions
RU2018144315A3 (ru
RU2740996C2 (ru
Inventor
Эдвард Б. РАЙЛИ
Луи НАУМОВСКИ
Кристиан Б. АЛЛАН
Цзеи ВАН
Марк Г. АНДЕРСОН
Дэниел Е. АФАР
Original Assignee
Эббви Байотерапьютикс Инк.
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Байотерапьютикс Инк., Эббви Инк. filed Critical Эббви Байотерапьютикс Инк.
Publication of RU2018144315A publication Critical patent/RU2018144315A/ru
Publication of RU2018144315A3 publication Critical patent/RU2018144315A3/ru
Application granted granted Critical
Publication of RU2740996C2 publication Critical patent/RU2740996C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Claims (62)

1. Конъюгат антитела к cMet и лекарственного средства ("ADC"), содержащий антимитотическое средство, связанное с антителом к cMet посредством линкера, где ADC характеризуется структурой формулы (I):
(I) [D-L-XY-]n-Ab,
или соответствующей ей соли, где
D представляет собой антимитотическое средство;
L представляет собой линкер;
Ab представляет собой антитело к cMet;
XY представляет собой ковалентную связь, связывающую линкер L с антителом Ab; и
n представляет собой целое число в диапазоне от 2 до 8;
где
L предусматривает валин-цитруллиновый (vc) линкер и характеризуется структурой формулы (IVb.2):
Figure 00000001
D представляет собой монометилауристатин E ("MMAE"), и ADC структурной формулы (I) характеризуется следующей структурой:
Figure 00000002
; и
Ab предусматривает антитело к cMet, которое содержит (i) VH-цепь, содержащую три CDR; и (ii) VL-цепь, содержащую три CDR, где
CDR №1 VH имеет аминокислотную последовательность: GYIFTAYTMH (SEQ ID NO: 112), CDR №2 VH имеет аминокислотную последовательность: WIKPNNGLANYAQKFQG (SEQ ID NO: 113), CDR №3 VH имеет аминокислотную последовательность: SEITTEFDY (SEQ ID NO: 114), CDR №1 VL имеет аминокислотную последовательность: KSSESVDSYANSFLH (SEQ ID NO: 115), CDR №2 VL имеет аминокислотную последовательность: RASTRES (SEQ ID NO: 116), и CDR №3 VL имеет аминокислотную последовательность: QQSKEDPLT (SEQ ID NO: 117),
и (iii) модифицированную шарнирную область, имеющую аминокислотную последовательность PKSCDCHCPPCP (SEQ ID NO: 170).
2. ADC по п. 1, где антитело к cMet содержит VH-цепь с SEQ ID NO: 78 и VL-цепь с SEQ ID NO: 79 или 81.
3. ADC по п. 1, где антитело к cMet содержит тяжелую цепь с SEQ ID NO: 86 или 88 и легкую цепь с SEQ ID NO: 87.
4. Фармацевтическая композиция, содержащая ADC по п. 3 и фармацевтически приемлемый носитель.
5. Фармацевтическая композиция по п. 4, характеризующаяся соотношением лекарственного средства и антитела ("DAR"), составляющим приблизительно 3,1.
6. Конъюгат антитела к cMet и лекарственного средства ("ADC"), содержащий сшивающее ДНК средство, связанное с антителом к cMet посредством линкера, где ADC характеризуется структурой формулы (I):
(I) [D-L-XY-]n-Ab,
или соответствующей ей соли, где
D представляет собой сшивающее ДНК средство;
L представляет собой линкер;
Ab представляет собой антитело к cMet;
XY представляет собой ковалентную связь, связывающую линкер L с антителом Ab; и
n представляет собой целое число в диапазоне от 2 до 8;
где
L предусматривает валин-аланиновый (va) линкер и характеризуется структурой формулы (IVd.3):
Figure 00000003
D представляет собой димер пирролобензодиазепина ("PBD"), и ADC структурной формулы (I) характеризуется следующей структурой:
Figure 00000004
Ab предусматривает антитело к cMet, которое содержит (i) VH-цепь, содержащую три CDR; и (ii) VL-цепь, содержащую три CDR, где
CDR №1 VH имеет аминокислотную последовательность: GYIFTAYTMH (SEQ ID NO: 173), CDR №2 VH имеет аминокислотную последовательность: WIKPNNGLANYAQKFQG (SEQ ID NO: 174), CDR №3 VH имеет аминокислотную последовательность: SEITTEFDY (SEQ ID NO: 175), CDR №1 VL имеет аминокислотную последовательность: KSSESVDSYANSFLH (SEQ ID NO: 176), CDR №2 VL имеет аминокислотную последовательность: RASTRES (SEQ ID NO: 177), и CDR №3 VL имеет аминокислотную последовательность: QQSKEDPLT (SEQ ID NO: 178),
и (iii) модифицированную шарнирную область, имеющую аминокислотную последовательность PKSCDCHCPPCP (SEQ ID NO: 170).
7. ADC по п. 6, где антитело к cMet содержит VH-цепь с SEQ ID NO: 78 и VL-цепь с SEQ ID NO: 79 или 81.
8. ADC по п. 6, где антитело к cMet содержит тяжелую цепь с SEQ ID NO: 171 и легкую цепь с SEQ ID NO: 172.
9. Способ лечения рака, представляющего собой солидную опухоль, при котором сверхэкспрессируется cMet, предусматривающий введение субъекту-человеку, у которого имеется указанный рак, фармацевтической композиции, содержащей конъюгат антитела к cMet и лекарственного средства ("ADC") и фармацевтически приемлемый носитель, где фармацевтическую композицию вводят в количестве и в течение периода времени, достаточных для обеспечения терапевтического эффекта, и где ADC характеризуется структурой формулы (I):
(I) [D-L-XY-]n-Ab,
или соответствующей ей соли, где
D представляет собой антимитотическое средство;
L представляет собой линкер;
Ab представляет собой антитело к cMet;
XY представляет собой ковалентную связь, связывающую линкер L с антителом Ab; и
n представляет собой целое число в диапазоне от 2 до 8;
где
L предусматривает валин-цитруллиновый (vc) линкер и характеризуется структурой формулы (IVb.2):
Figure 00000005
D представляет собой монометилауристатин E ("MMAE"), и ADC структурной формулы (I) характеризуется следующей структурой:
Figure 00000002
; и
Ab предусматривает антитело к cMet, которое содержит (i) VH-цепь, содержащую три CDR; и (ii) VL-цепь, содержащую три CDR, где
CDR №1 VH имеет аминокислотную последовательность: GYIFTAYTMH (SEQ ID NO: 112), CDR №2 VH имеет аминокислотную последовательность: WIKPNNGLANYAQKFQG (SEQ ID NO: 113), CDR №3 VH имеет аминокислотную последовательность: SEITTEFDY (SEQ ID NO: 114), CDR №1 VL имеет аминокислотную последовательность: KSSESVDSYANSFLH (SEQ ID NO: 115), CDR №2 VL имеет аминокислотную последовательность: RASTRES (SEQ ID NO: 116), и CDR №3 VL имеет аминокислотную последовательность: QQSKEDPLT (SEQ ID NO: 117),
и (iii) модифицированную шарнирную область, имеющую аминокислотную последовательность PKSCDCHCPPCP (SEQ ID NO: 170).
10. Способ по п. 9, где антитело к cMet содержит VH-цепь с SEQ ID NO: 78 и VL-цепь с SEQ ID NO: 79 или 81.
11. Способ по п. 9, где антитело к cMet содержит тяжелую цепь с SEQ ID NO: 86 или 88 и легкую цепь с SEQ ID NO: 87.
12. Способ по п. 9, где рак, характеризующийся сверхэкспрессией cMet, представляет собой немелкоклеточный рак легкого ("NSCLC").
13. Способ по п. 12, где NSCLC представляет собой плоскоклеточный NSCLC или аденокарциному.
14. Способ по п. 13, где плоскоклеточный NSCLC характеризуется IHC-показателем, составляющим от 2+ до 3+, у биоптата.
15. Способ по п. 13, где биоптат ткани опухоли, представляющей собой аденокарциному, характеризуется IHC-показателем, составляющим 3+, и/или H-показателем, превышающим 225.
16. Способ по п. 9, где ADC, нацеливающийся на cMet, вводят в дополнение к дополнительному противораковому средству.
17. Способ по п. 16, где дополнительное противораковое средство представляет собой ингибитор рецептора эпидермального фактора роста ("EGFR").
18. Способ по п. 17, где дополнительное противораковое средство представляет собой эрлотиниб.
RU2018144315A 2016-05-17 2017-05-17 КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ RU2740996C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662337796P 2016-05-17 2016-05-17
US62/337,796 2016-05-17
PCT/US2017/033176 WO2017201204A1 (en) 2016-05-17 2017-05-17 ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

Publications (3)

Publication Number Publication Date
RU2018144315A true RU2018144315A (ru) 2020-06-17
RU2018144315A3 RU2018144315A3 (ru) 2020-07-22
RU2740996C2 RU2740996C2 (ru) 2021-01-22

Family

ID=59014737

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018144315A RU2740996C2 (ru) 2016-05-17 2017-05-17 КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (25)

Country Link
US (5) US20170348429A1 (ru)
EP (4) EP4233909A3 (ru)
JP (4) JP2019521087A (ru)
KR (3) KR102449294B1 (ru)
CN (3) CN114246953B (ru)
AU (1) AU2017268342B2 (ru)
BR (1) BR112018073574A2 (ru)
CA (1) CA3024386C (ru)
CY (2) CY1123256T1 (ru)
DK (2) DK3626273T3 (ru)
ES (2) ES2811351T3 (ru)
HR (2) HRP20201186T1 (ru)
HU (2) HUE050398T2 (ru)
IL (3) IL294146B2 (ru)
LT (2) LT3626273T (ru)
MX (1) MX2018014175A (ru)
NZ (1) NZ748314A (ru)
PL (2) PL3458102T3 (ru)
PT (2) PT3458102T (ru)
RS (2) RS61659B1 (ru)
RU (1) RU2740996C2 (ru)
SG (2) SG10201914095SA (ru)
SI (2) SI3626273T1 (ru)
WO (1) WO2017201204A1 (ru)
ZA (1) ZA201808386B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233909A3 (en) * 2016-05-17 2023-09-20 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP6951441B2 (ja) * 2016-11-23 2021-10-20 イーライ リリー アンド カンパニー Ｍｅｔ抗体薬物複合体
CN110144325A (zh) * 2018-02-12 2019-08-20 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
RS64690B1 (sr) 2018-03-13 2023-11-30 Zymeworks Bc Inc Konjugati biparatopskog anti-her2 antitela i leka i postupci za njihovu upotrebu
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
MA52238A (fr) * 2018-03-28 2021-02-17 Mitsubishi Tanabe Pharma Corp Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées
BR112021004829A2 (pt) * 2018-09-30 2021-06-08 Jiangsu Hengrui Medicine Co., Ltd. conjugado de anticorpo anti-b7h3-análogo de exatecano e uso medicinal do mesmo
KR102353568B1 (ko) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
JP2022547274A (ja) 2019-09-16 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
CN112604004B (zh) * 2019-09-19 2022-05-10 中国医学科学院医药生物技术研究所 一类抗人egfr抗体药物偶联物及其制备方法与应用
CN110893236A (zh) * 2019-10-09 2020-03-20 中山大学 溶酶体靶向的抗体药物偶联物及其应用
KR20230008830A (ko) 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
AU2021337718A1 (en) * 2020-09-01 2022-07-07 Remegen Co., Ltd. Anti-c-Met antibody-drug conjugate and applications thereof
WO2022078279A1 (zh) * 2020-10-12 2022-04-21 昆山新蕴达生物科技有限公司 抗体-药物偶联物及其应用
CN114533891B (zh) * 2020-11-24 2023-04-18 深圳先进技术研究院 一种靶向无痕释放药物缀合物及其制备方法与应用
AU2022218165B2 (en) * 2021-02-03 2024-02-29 Mythic Therapeutics, Inc. Anti-met antibodies and uses thereof
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
BR112023020562A2 (pt) * 2021-04-06 2023-12-05 Abbvie Biotherapeutics Inc Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina
AU2022254042A1 (en) 2021-04-07 2023-09-14 Mythic Therapeutics, Inc. Antigen-binding protein constructs and antibodies and uses thereof
AU2022254291A1 (en) 2021-04-08 2023-10-12 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
AU2022388735A1 (en) 2021-11-09 2024-05-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
US20230285394A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib
WO2024065056A1 (en) * 2022-09-28 2024-04-04 Zymeworks Bc Inc. Antibody drug conjugates targeting c-met and methods of use
WO2024081729A2 (en) 2022-10-12 2024-04-18 Mythic Therapeutics, Inc. Lrrc-15-binding protein constructs and uses thereof
WO2024129585A1 (en) * 2022-12-11 2024-06-20 Mythic Therapeutics, Inc. ANTI-cMET ANTIBODY DRUG CONJUGATES AND THERAPEUTIC USES THEREOF
FI20235292A1 (en) * 2023-03-13 2024-09-14 Glykos Finland Oy ANTIBODY SEXATECANE CONJUGATE

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
PL193780B1 (pl) 1997-04-14 2007-03-30 Micromet Ag Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP1594542B1 (en) 2003-02-20 2010-06-30 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer
CN102675462A (zh) * 2003-06-27 2012-09-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
CA3062320C (en) * 2003-11-06 2022-11-15 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2558399C (en) * 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine-manipulated antibodies and conjugates
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
RU2489423C2 (ru) 2006-02-02 2013-08-10 Синтарга Б.В. Водорастворимые аналоги сс-1065 и их конъюгаты
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
MX2010005857A (es) 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US20100152725A1 (en) 2008-12-12 2010-06-17 Angiodynamics, Inc. Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation
US8524214B2 (en) 2009-05-28 2013-09-03 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
JP5687206B2 (ja) 2009-12-07 2015-03-18 株式会社Ｎｔｔドコモ 伝搬経路推定方法、プログラム及び装置
WO2011111020A1 (en) 2010-03-10 2011-09-15 Novartis Ag Streptococcus thermophilus bacterium
CA2794307A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
DE102010012915A1 (de) 2010-03-26 2011-09-29 Schaeffler Technologies Gmbh & Co. Kg Vorrichtung und Verfahren zur Ermittlung eines Schädigungszustands eines Radlagers
EP2402370A1 (en) 2010-06-29 2012-01-04 Pierre Fabre Médicament Novel antibody for the diagnosis and/or prognosis of cancer
HUE045348T2 (hu) * 2011-05-08 2019-12-30 Legochem Biosciences Inc Fehérje-hatóanyag konjugátumok és eljárás elõállításukra
BR112013031819B1 (pt) 2011-06-10 2022-05-03 Mersana Therapeutics, Inc Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US20130224228A1 (en) 2011-12-05 2013-08-29 Igenica, Inc. Antibody-Drug Conjugates and Related Compounds, Compositions, and Methods
KR20140121827A (ko) 2011-12-23 2014-10-16 메르사나 테라퓨틱스, 인코포레이티드 퓨마질린 유도체-phf 결합체의 약제학적 제형
MX353608B (es) * 2012-02-24 2018-01-19 Alteogen Inc Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo.
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2014008375A1 (en) 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
EP2928503B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Conjugates of auristatin compounds
JP6334553B2 (ja) 2012-12-10 2018-05-30 メルサナ セラピューティクス，インコーポレイティド タンパク質−高分子−薬剤コンジュゲート
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
JP6382935B2 (ja) * 2013-03-15 2018-08-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 抗ｅｇｆｒ抗体薬物複合体製剤
KR102150616B1 (ko) * 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
KR102200274B1 (ko) 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
CN106188293A (zh) * 2015-04-17 2016-12-07 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
WO2016165580A1 (zh) * 2015-04-17 2016-10-20 江苏恒瑞医药股份有限公司 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途
EP4233909A3 (en) * 2016-05-17 2023-09-20 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use

Also Published As

Publication number Publication date
CN114246953A (zh) 2022-03-29
JP2019521087A (ja) 2019-07-25
KR102512597B1 (ko) 2023-03-23
US20200215200A1 (en) 2020-07-09
KR102449294B1 (ko) 2022-09-30
DK3626273T3 (da) 2021-02-08
ZA201808386B (en) 2022-07-27
US20170348429A1 (en) 2017-12-07
SI3458102T1 (sl) 2020-09-30
IL294146A (en) 2022-08-01
EP4233909A2 (en) 2023-08-30
JP2021073247A (ja) 2021-05-13
HRP20210326T1 (hr) 2021-04-02
KR20190008339A (ko) 2019-01-23
PL3626273T3 (pl) 2021-06-14
ES2811351T3 (es) 2021-03-11
LT3626273T (lt) 2021-03-10
EP3804765A1 (en) 2021-04-14
HRP20201186T1 (hr) 2020-11-13
SI3626273T1 (sl) 2021-04-30
CA3024386C (en) 2024-01-02
MX2018014175A (es) 2020-02-07
CA3024386A1 (en) 2017-11-23
CN114246953B (zh) 2024-07-09
US20190314518A1 (en) 2019-10-17
NZ748314A (en) 2023-07-28
RU2018144315A3 (ru) 2020-07-22
JP2022185003A (ja) 2022-12-13
SG10201914095SA (en) 2020-03-30
LT3458102T (lt) 2020-08-25
CN109562189B (zh) 2021-12-31
PT3626273T (pt) 2021-03-09
AU2017268342B2 (en) 2023-08-17
CN114177308A (zh) 2022-03-15
EP3626273A1 (en) 2020-03-25
EP3458102B1 (en) 2020-06-17
US10603389B2 (en) 2020-03-31
IL294146B2 (en) 2024-01-01
BR112018073574A2 (pt) 2019-03-19
WO2017201204A1 (en) 2017-11-23
JP6870161B1 (ja) 2021-05-12
HUE053332T2 (hu) 2021-06-28
ES2864150T3 (es) 2021-10-13
US10383948B2 (en) 2019-08-20
RS61659B1 (sr) 2021-04-29
CY1123256T1 (el) 2021-10-29
KR20230028574A (ko) 2023-02-28
CN114177308B (zh) 2024-07-09
EP3458102A1 (en) 2019-03-27
EP4233909A3 (en) 2023-09-20
EP3626273B1 (en) 2020-12-30
JP2021107424A (ja) 2021-07-29
DK3458102T3 (da) 2020-07-27
US20230321271A1 (en) 2023-10-12
IL262869A (en) 2018-12-31
RS60663B1 (sr) 2020-09-30
CY1123858T1 (el) 2022-05-27
PL3458102T3 (pl) 2020-12-14
CN109562189A (zh) 2019-04-02
JP7150087B2 (ja) 2022-10-07
KR20220137158A (ko) 2022-10-11
IL294146B1 (en) 2023-09-01
IL262869B (en) 2022-07-01
IL304717A (en) 2023-09-01
PT3458102T (pt) 2020-08-17
US20180250418A1 (en) 2018-09-06
AU2017268342A1 (en) 2018-11-29
SG11201810034XA (en) 2018-12-28
RU2740996C2 (ru) 2021-01-22
HUE050398T2 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
RU2018144315A (ru) КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2020130125A1 (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
JP7458981B2 (ja) 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
WO2020122034A1 (ja) 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
RU2492860C2 (ru) Антиопластические комбинации, содержащие нкi-272 и винорелбин
EP3042669B1 (en) Antitumor agent and antitumor effect enhancer
Mer et al. Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
Moehler et al. New chemotherapeutic strategies in colorectal cancer
KR102694803B1 (ko) A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용
WO2024193570A1 (en) Combination of antibody-drug conjugate and cancer therapy, and use thereof
JP2021508699A (ja) トリプルネガティブ乳がんを処置するためのｐｄ−１抗体及びアパチニブの併用処置の使用
JP2024161445A (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
WO2023209591A1 (en) Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor